Navigation Links
Newly released FDA draft guidelines for biosimilar drugs to be discussed at conference
Date:3/1/2012

On March 9, the New York Academy of Sciences will present "Scientific Considerations for Complex Drugs in Light of Established Regulatory Guidance." This full-day conference will explore current definitions, global scientific and regulatory hurdles, and future challenges for follow-on versions of complex drugs.

On February 9, 2012, the FDA released its much-anticipated new draft guidelines for implementing the Biologics Price Competition and Innovation Act of 2009, which called for an abbreviated approval pathway for biological products that are demonstrated to be "highly similar" to, or "interchangeable" with, a previously approved and regulated drug. However, current U.S. regulations do not make scientific distinctions between small-molecule drugs and non-biological complex drugs; although the latter may present many of the same scientific and clinical challenges to reproduce as biologics.

In light of the recently drafted approval guidelines for biosimilars in the U.S., and increased international concern for new follow-on biological and non-biological products currently defined as "interchangeable" in both established and emerging markets abroad, the Academy will bring together experts representing a variety of perspectives, including industry, regulatory agencies, physicians, and consumers. Representation from the FDA will provide an overview of the demonstration of therapeutic equivalence of complex drug products, which shall inform the day's broader discussions about the regulation of non-biological complex drugs.

Plenary sessions will address the most recent regulatory developments and experimental design, interchangeability, and immunogenicity issues for follow-on versions of complex drugs; featuring conversations led by Larry Lee, PhD, FDA; Ivana Knezevic, MD, PhD, World Health Organization; Huub Schellekens, MD, PhD, Utrecht University; Janet S. Wyatt, PhD, RN, FAANP, Institute of Pediatric Nursing and Arthritis Foundation; Jan Mueller-Berghaus, MD, Paul-Ehrlich-Institut; Beatriz Silva-Lima, PharmD, PhD, University of Lisbon; Chris Holloway, PhD, ERA Consulting Group; and Andrew D. Zelenetz, MD, PhD, Memorial Sloan-Kettering Cancer Center.

An international audience of basic researchers, policy makers, and regulatory and public health experts from academia, industry, government, and NGOs will participate in the conversation about the changing regulatory landscape for biological and non-biological complex drugs. The open format of the meeting, including multiple question and answer periods and a working lunch brainstorming session culminating in a full-meeting discussion, will foster dialogue between disparate groups that may aid in defining and determining the criteria for follow-on complex drugs and help move U.S. policy forward.
'/>"/>

Contact: Melinda Miller
mmiller@nyas.org
New York Academy of Sciences
Source:Eurekalert

Related biology news :

1. Newly-discovered mechanism can explain the Beckwith-Wiedemann syndrome
2. Newly identified gene powerful predictor of colon cancer metastasis
3. Newly found enzymes may play early role in cancer
4. Obesity starts in the head? 6 newly discovered genes for obesity have a neural effect
5. UC Davis research shows that newly discovered drug reduces heart enlargement
6. Newly described contaminant sources in Katrina-flooded homes pose health risks
7. DNA evidence is in, newly discovered species of fish dubbed H. psychedelica
8. Newly discovered gene plays vital role in cancer
9. Newly discovered epidermal growth factor receptor active in human pancreatic cancers
10. Newly discovered reactions from an old drug may lead to new antibiotics
11. Newly discovered snow roots are evolutionary phenomenon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... ... innovative medical technologies, services and solutions to the healthcare market. The company's primary ... various distribution, manufacturing, sales and marketing strategies that are necessary to help companies ...
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
Breaking Biology Technology: